-
-
-
-
-
-
-
FDA clears Dexcom's over-the-counter glucose monitor for children
-
-
-
-
-
-
-
DexCom (DXCM) PT Lowered to $82 at Canaccord
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on DexCom (DXCM)
-
-
-
-
-
-
-
Evercore ISI Upgrades DexCom (DXCM) to Outperform, 'Turning the page to T2 NIT expansion'
-
-
-
-
-
-
-
Barclays Downgrades Insulet Corporation (PODD) to Underweight
-
-
-
-
-
-
-
BofA’s six MedTech picks for 2026 on strong earnings growth
-
-
-
-
-
-
-
Dexcom receives FDA clearance for basal insulin dosing optimizer
-
428,515 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

